171 related articles for article (PubMed ID: 37969363)
1. A deep learning-based model (DeepMPM) to help predict survival in patients with malignant pleural mesothelioma.
Li W; Zhang M; Cai S; Li S; Yang B; Zhou S; Pan Y; Xu S
Transl Cancer Res; 2023 Oct; 12(10):2887-2897. PubMed ID: 37969363
[TBL] [Abstract][Full Text] [Related]
2. The use of a next-generation sequencing-derived machine-learning risk-prediction model (OncoCast-MPM) for malignant pleural mesothelioma: a retrospective study.
Zauderer MG; Martin A; Egger J; Rizvi H; Offin M; Rimner A; Adusumilli PS; Rusch VW; Kris MG; Sauter JL; Ladanyi M; Shen R
Lancet Digit Health; 2021 Sep; 3(9):e565-e576. PubMed ID: 34332931
[TBL] [Abstract][Full Text] [Related]
3. Treatment patterns and outcomes for patients with malignant pleural mesothelioma in England in 2013-2017: A nationwide CAS registry analysis from the I-O Optimise initiative.
Baas P; Daumont MJ; Lacoin L; Penrod JR; Carroll R; Venkatesan S; Ubhi H; Calleja A; Snee M
Lung Cancer; 2021 Dec; 162():185-193. PubMed ID: 34823894
[TBL] [Abstract][Full Text] [Related]
4. Establishment of predictive nomogram and web-based survival risk calculator for malignant pleural mesothelioma: A SEER database analysis.
Chen S; Yu W; Shao S; Xiao J; Bai H; Pu Y; Li M
Front Oncol; 2022; 12():1027149. PubMed ID: 36276110
[TBL] [Abstract][Full Text] [Related]
5. A Nomogram to Predict Prognosis in Malignant Pleural Mesothelioma.
Wang S; Ma K; Chen Z; Yang X; Sun F; Jin Y; Shi Y; Jiang W; Wang Q; Zhan C
World J Surg; 2018 Jul; 42(7):2134-2142. PubMed ID: 29282508
[TBL] [Abstract][Full Text] [Related]
6. Deep learning model for predicting the survival of patients with primary gastrointestinal lymphoma based on the SEER database and a multicentre external validation cohort.
Wang F; Chen L; Liu L; Jia Y; Li W; Wang L; Zhi J; Liu W; Li W; Li Z
J Cancer Res Clin Oncol; 2023 Oct; 149(13):12177-12189. PubMed ID: 37428248
[TBL] [Abstract][Full Text] [Related]
7. An Investigation of Cancer-Directed Surgery for Different Histologic Subtypes of Malignant Pleural Mesothelioma.
Mansur A; Potter AL; Zurovec AJ; Nathamuni KV; Meyerhoff RR; Berry MF; Kang A; Jeffrey Yang CF
Chest; 2023 May; 163(5):1292-1303. PubMed ID: 36574925
[TBL] [Abstract][Full Text] [Related]
8. Survival by Histologic Subtype of Malignant Pleural Mesothelioma and the Impact of Surgical Resection on Overall Survival.
Verma V; Ahern CA; Berlind CG; Lindsay WD; Shabason J; Sharma S; Culligan MJ; Grover S; Friedberg JS; Simone CB
Clin Lung Cancer; 2018 Nov; 19(6):e901-e912. PubMed ID: 30224273
[TBL] [Abstract][Full Text] [Related]
9. Establishment and validation of nomograms to predict survival probability of advanced malignant pleural mesothelioma based on the SEER database and a Chinese medical institution.
Zhang X; Chang L; Zhu Y; Mao Y; Zhang T; Zhang Q; Wang C
Front Endocrinol (Lausanne); 2023; 14():1139222. PubMed ID: 37124752
[TBL] [Abstract][Full Text] [Related]
10. Survival analysis via nomogram of surgical patients with malignant pleural mesothelioma in the Surveillance, Epidemiology, and End Results database.
Zhuo M; Zheng Q; Chi Y; Jia B; Zhao J; Wu M; An T; Wang Y; Li J; Zhao X; Yang X; Zhong J; Chen H; Dong Z; Wang J; Zhai X; Wang Z
Thorac Cancer; 2019 May; 10(5):1193-1202. PubMed ID: 30951250
[TBL] [Abstract][Full Text] [Related]
11. Disparities in Survival Due to Social Determinants of Health and Access to Treatment in US Patients With Operable Malignant Pleural Mesothelioma.
Alnajar A; Kareff SA; Razi SS; Rao JS; De Lima Lopes G; Nguyen DM; Villamizar N; Rodriguez E
JAMA Netw Open; 2023 Mar; 6(3):e234261. PubMed ID: 36951862
[TBL] [Abstract][Full Text] [Related]
12. Combined modality treatment for malignant pleural mesothelioma: a single-centre long-term survival analysis using extrapleural pneumonectomy.
Frick AE; Nackaerts K; Moons J; Lievens Y; Verbeken E; Lambrecht M; Coolen J; Dooms C; Vansteenkiste J; De Leyn P; Nafteux P
Eur J Cardiothorac Surg; 2019 May; 55(5):934-941. PubMed ID: 30535191
[TBL] [Abstract][Full Text] [Related]
13. Chemotherapy Versus Supportive Care for Unresected Malignant Pleural Mesothelioma.
Verma V; Wegner RE; Brooks ED; Miccio JA; Kann BH; Finley GG; Raj MS; Grover S; Mohindra P; Simone CB
Clin Lung Cancer; 2019 Jul; 20(4):263-269. PubMed ID: 30992187
[TBL] [Abstract][Full Text] [Related]
14. Addition of radiotherapy to surgery and chemotherapy improves survival in localized malignant pleural mesothelioma: A Surveillance, Epidemiology, and End Results (SEER) study.
Thompson AB; Quinn TJ; Siddiqui ZA; Almahariq MF; Grills IS; Stevens CW
Lung Cancer; 2020 Aug; 146():120-126. PubMed ID: 32531717
[TBL] [Abstract][Full Text] [Related]
15. Treatment patterns and outcomes in older patients with advanced malignant pleural mesothelioma: Analyses of Surveillance, Epidemiology, and End Results-Medicare data.
Danese MD; Daumont M; Nwokeji E; Gleeson M; Penrod JR; Lubeck D
Cancer Rep (Hoboken); 2022 Sep; 5(9):e1568. PubMed ID: 34698447
[TBL] [Abstract][Full Text] [Related]
16. [Development and validation of prognostic nomogram for malignant pleural mesothelioma].
Xie XJ; Chen JY; Jiang J; Duan H; Wu Y; Zhang XW; Yang SJ; Zhao W; Shen SS; Wu L; He B; Ding YY; Luo H; Liu SY; Han D
Zhonghua Zhong Liu Za Zhi; 2023 May; 45(5):415-423. PubMed ID: 37188627
[No Abstract] [Full Text] [Related]
17. Predictors of Survival among Male and Female Patients with Malignant Pleural Mesothelioma: A Random Survival Forest Analysis of Data from the 2000-2017 Surveillance, Epidemiology, and End Results Program.
Liu B; Niu L; Boscoe F; Lee FF
J Registry Manag; 2021; 48(3):118-125. PubMed ID: 35413729
[TBL] [Abstract][Full Text] [Related]
18. Does the LENT score risk-stratify patients with malignant pleural mesothelioma? An observational study.
Chollet B; Guinde J; Laroumagne S; Dutau H; Astoul P
Thorac Cancer; 2021 Jun; 12(11):1752-1756. PubMed ID: 33949775
[TBL] [Abstract][Full Text] [Related]
19. Deep-learning model for predicting the survival of rectal adenocarcinoma patients based on a surveillance, epidemiology, and end results analysis.
Yu H; Huang T; Feng B; Lyu J
BMC Cancer; 2022 Feb; 22(1):210. PubMed ID: 35216571
[TBL] [Abstract][Full Text] [Related]
20. A prognostic score for patients with malignant pleural mesothelioma (MPM) receiving second-line immunotherapy or chemotherapy in the ETOP 9-15 PROMISE-meso phase III trial.
Banna GL; Addeo A; Zygoura P; Tsourti Z; Popat S; Curioni-Fontecedro A; Nadal E; Shah R; Pope A; Fisher P; Spicer J; Roy A; Gilligan D; Gautschi O; Janthur WD; López-Castro R; Roschitzki-Voser H; Dafni U; Peters S; Stahel RA
Lung Cancer; 2022 Jul; 169():77-83. PubMed ID: 35660972
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
